Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ascendis Pharma A/S - Ordinary Share
(NQ:
ASND
)
236.55
-28.37 (-10.71%)
Streaming Delayed Price
Updated: 2:13 PM EDT, Sep 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,821,192
Open
257.17
Bid (Size)
236.05 (200)
Ask (Size)
237.00 (200)
Prev. Close
264.92
Today's Range
228.56 - 257.53
52wk Range
186.05 - 282.15
Shares Outstanding
57,152,295
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Ascendis Pharma (NASDAQ:ASND): Strong Growth Meets a High-Quality Technical Setup
↗
September 14, 2026
Via
Chartmill
Ascendis Pharma (NASDAQ:ASND): A Fitting Candidate for Affordable Growth Investors
↗
September 09, 2026
Via
Chartmill
Performance
YTD
+10.9%
+10.9%
1 Month
-4.4%
-4.4%
3 Month
+5.9%
+5.9%
6 Month
+2.4%
+2.4%
1 Year
+21.5%
+21.5%
More News
Read More
Ascendis Pharma (NASDAQ:ASND) Passes Minervini Trend Template and High Growth Momentum Screen
↗
September 01, 2026
Via
Chartmill
If You Invested $1000 In Ascendis Pharma Stock 10 Years Ago, You Would Have This Much Today
↗
August 26, 2026
Via
Benzinga
Ascendis Pharma (ASND) Q2 2026 Earnings Call Transcript
↗
August 20, 2026
Via
The Motley Fool
Topics
Earnings
Ascendis Pharma (NASDAQ:ASND) Combines High Growth Momentum with a Breakout Setup
↗
August 11, 2026
Via
Chartmill
Ascendis Pharma (ASND) Shows High Growth Momentum With Bull Flag Breakout Setup
↗
July 20, 2026
Via
Chartmill
ASCENDIS PHARMA A/S (NASDAQ:ASND) Screens as a High-Growth Momentum Candidate
↗
May 18, 2026
Via
Chartmill
Ascendis Pharma (NASDAQ:ASND) Shares Drop After Q4 Earnings Miss on Wider-Than-Expected Loss
↗
February 11, 2026
Via
Chartmill
Topics
Earnings
Eyconis Announces Initiation of First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet Age-Related Macular Degeneration Patients
August 18, 2026
From
Eyconis Inc.
Via
GlobeNewswire
Ascendis Pharma A/S Q2 Earnings Call Highlights
↗
August 13, 2026
Via
MarketBeat
Topics
Earnings
Here's How Much $100 Invested In Ascendis Pharma 5 Years Ago Would Be Worth Today
↗
August 11, 2026
Via
Benzinga
What to Know About This Fund’s $50 Million Exit From Ascendis Pharma
↗
May 14, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) Combines Minervini Trend Template with High Growth Momentum
↗
January 28, 2026
Via
Chartmill
Energy Fund Yielding 7% and Up 14% in a Year Still Wasn’t Enough to Stop This $3 Million Exit
↗
May 09, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Ascendis (ASND) Q1 2026 Earnings Call Transcript
↗
May 08, 2026
Via
The Motley Fool
Topics
Earnings
Ascendis Pharma Completes Strategic Trifecta with U.S. Launch of YUVIWEL and Seven-Year Orphan Exclusivity
April 13, 2026
Via
MarketMinute
Topics
Economy
Agriculture Stock Up 53% Draws $12 Million Bet. Here's What Long-Term Investors Should Know
↗
March 20, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Ascendis (ASND) Q4 2025 Earnings Call Transcript
↗
February 23, 2026
Via
The Motley Fool
Topics
Earnings
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million
↗
February 22, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position
↗
February 22, 2026
Via
The Motley Fool
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction
↗
February 22, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges
↗
February 22, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Ascendis Pharma (ASND) Q4 2025 Earnings Transcript
↗
February 11, 2026
Via
The Motley Fool
Ascendis Pharma (NASDAQ:ASND) Passes Minervini's Trend Template and High Growth Momentum Scan
↗
December 25, 2025
Via
Chartmill
Frequently Asked Questions
Is Ascendis Pharma A/S - Ordinary Share publicly traded?
Yes, Ascendis Pharma A/S - Ordinary Share is publicly traded.
What exchange does Ascendis Pharma A/S - Ordinary Share trade on?
Ascendis Pharma A/S - Ordinary Share trades on the Nasdaq Stock Market
What is the ticker symbol for Ascendis Pharma A/S - Ordinary Share?
The ticker symbol for Ascendis Pharma A/S - Ordinary Share is ASND on the Nasdaq Stock Market
What is the current price of Ascendis Pharma A/S - Ordinary Share?
The current price of Ascendis Pharma A/S - Ordinary Share is 236.55
When was Ascendis Pharma A/S - Ordinary Share last traded?
The last trade of Ascendis Pharma A/S - Ordinary Share was at 09/15/26 02:13 PM ET
What is the market capitalization of Ascendis Pharma A/S - Ordinary Share?
The market capitalization of Ascendis Pharma A/S - Ordinary Share is 13.52B
How many shares of Ascendis Pharma A/S - Ordinary Share are outstanding?
Ascendis Pharma A/S - Ordinary Share has 14B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
